Clinical Trial Update: A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of epcoritamab and ibrutinib in patients with central nervous system lymphomas, sponsored by Memorial Sloan Kettering C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Status: RECRUITING